Welcome to our dedicated page for Clarivate Plc news (Ticker: CLVT), a resource for investors and traders seeking the latest updates and insights on Clarivate Plc stock.
Clarivate Plc (NYSE: CLVT) is described as a leading global provider of transformative intelligence, with news that reflects its activities across Academia & Government, Intellectual Property and Life Sciences & Healthcare. Company announcements frequently highlight new AI-powered tools, analytical reports and customer adoptions that illustrate how Clarivate combines enriched data, analytics and workflow software.
Recent news includes the launch of the Web of Science Research Assistant, a generative AI-powered tool that helps researchers conduct natural-language searches, perform literature reviews and explore visualizations based on more than 120 years of publication and citation data. Clarivate also reports on studies such as the Pulse of the Library report, which surveys thousands of librarians worldwide about AI adoption, open science and budget pressures, and on the annual Highly Cited Researchers list, which recognizes researchers whose work has had broad influence based on Web of Science data.
In Intellectual Property, Clarivate issues updates on solutions like IPfolio and Derwent Patent Monitor, including customer selections by organizations such as Nissan Motor Co., Ltd. and FUJIFILM Holdings Corporation. These stories emphasize how IP management platforms and AI-enabled patent review tools support more efficient IP operations and collaboration between IP and R&D teams.
Life sciences and healthcare news often centers on Clarivate analyses such as the Drugs to Watch report and Companies to Watch reports, which identify emerging therapies and innovative companies using integrated, AI-enhanced datasets. Visitors to this news page can follow Clarivate’s product launches, research reports, customer case studies and investor-related announcements to understand how the company is applying data and AI across its core markets.
Clarivate (NYSE: CLVT) announced on March 10, 2026 that Cortellis Regulatory Intelligence (CRI) will integrate with Anthropic's Claude via the open Model Context Protocol (MCP).
This integration embeds authoritative regulatory content into Claude workflows, giving life sciences teams access to referenced regulatory answers and enabling CRI to work alongside internal data and agents.
Clarivate (NYSE: CLVT) announced that Jonathan Collins, Executive Vice President and Chief Financial Officer, will present at the Wolfe Research FinTech Forum on March 10, 2026 at 10:55 AM ET.
The presentation will be webcast live with a replay available on the company's investor site and the event platform, remaining accessible for 90 days.
Clarivate (NYSE: CLVT) reported fourth-quarter and full-year 2025 results, highlighting improved cash generation and a shift to subscription revenue. Total 2025 revenue was $2,455.2M, organic ACV rose 1.8%, and free cash flow reached $365.3M. The company is pursuing a sale of its Life Sciences & Healthcare business and provided 2026 guidance projecting organic ACV 2.0–3.0% and Adjusted EBITDA $980M–$1.04B.
The company returned ~$225M to shareholders via buybacks and reduced debt through accelerated repayments, while forecasting stronger margins and ~10% free cash flow growth in 2026.
Clarivate (NYSE: CLVT) released a video webinar, Intelligence Amplified in the Age of AI, on February 3, 2026, explaining how its proprietary data and AI capabilities support research, IP, and life sciences workflows. The session details AI Research Assistants, AI Workflow Agents, and AI Ecosystem Access.
The webinar emphasizes 97% revenue from proprietary solutions and how curated, structured data reduces hallucination risks in high‑stakes decisions.
Clarivate (NYSE: CLVT) announced that subsidiary Camelot Finance S.A. fully redeemed the remaining $100 million aggregate principal of its 4.50% senior secured notes due 2026 on Jan 30, 2026, paying 100% of principal plus accrued interest.
The redemption was funded with cash on hand and is part of Clarivate's capital allocation strategy, which also included repurchasing ~56 million ordinary shares for $225 million in 2025 (including ~21 million shares for $75 million in Q4 2025).
Clarivate (NYSE: CLVT) will report fourth quarter and full year 2025 results before the market opens on Tuesday, February 24, 2026. The company will publish a press release and earnings supplement and host a live conference call and webcast at 9:00 AM ET.
The live webcast and audio broadcast will be available via Clarivate investor relations and a replay will be posted two hours after the call and remain available for one year.
Clarivate (NYSE: CLVT) announced Clarivate Nexus, an academic assistant that embeds library content and services into AI tools, web environments, and campus systems to reconnect students and researchers with trusted scholarly resources.
Core features include unified library access, full-text linking from AI outputs, source verification and citation support, literature recommendations, and surfaced library services. Nexus will launch as a browser extension with a planned early access release in Q3 2026 and later support direct campus integrations. The product emphasizes entitlement-aware access, user privacy, and library branding, and is built on Clarivate indexes including Web of Science and ProQuest collections.
Clarivate (NYSE:CLVT) published the 15th Top 100 Global Innovators list on January 21, 2026, highlighting organizations that lead high-strength invention activity.
The 2026 report finds that the Top 100 account for 16% of the world’s strongest AI inventions, AI filings have doubled repeatedly since 2019 with over one million invention specifications published by mid-2025, and Samsung Electronics retains the #1 rank. Japan leads with 32 organizations on the list; the United States lists 18 organizations overall but holds only one of the top 10 positions. Six new entrants and six re-entrants are named, and 16 organizations are all-time recipients.
MongoDB (NASDAQ: MDB) expanded its AI capabilities on Jan 15, 2026 by integrating Voyage AI embedding and reranking models into MongoDB Atlas and Community deployments to enable production-ready retrieval tasks without moving data.
Key launches include five Voyage 4 embedding models (voyage-4, voyage-4-large, voyage-4-lite, voyage-4-nano, and multimodal-3.5), Automated Embedding for MongoDB Vector Search (public preview), Atlas embedding and reranking APIs, and an AI assistant for Compass and Atlas Data Explorer. MongoDB said these features aim to reduce latency, simplify architectures, and improve retrieval accuracy for customers (60,000+ users).
Clarivate (NYSE: CLVT) released its Drugs to Watch 2026 report on January 6, 2026, identifying eleven therapies that may reach blockbuster status or transform care within five years (blockbuster defined as ≥USD 1 billion annual sales).
The report covers advances across metabolic disease, oncology, immunology, rare conditions and protein degraders, cites over 160 analysts reviewing hundreds of drugs using ten AI-enhanced datasets, and highlights delivery innovation and Mainland China as a growing commercial and innovation force.